title: The JAK2V617F mutation can occur in a hematopoietic stem cell that exhibits no proliferative advantage: a case of human allogeneic transplantation.
authors.forename: Kristien
authors.initials: K
authors.lastname: Van Pelt
authors.forename: Friedel
authors.initials: F
authors.lastname: Nollet
authors.forename: Dominik
authors.initials: D
authors.lastname: Selleslag
authors.forename: Laurent
authors.initials: L
authors.lastname: Knoops
authors.forename: Stefan N
authors.initials: SN
authors.lastname: Constantinescu
authors.forename: Arnold
authors.initials: A
authors.lastname: Criel
authors.forename: Johan
authors.initials: J
authors.lastname: Billiet
mesh_terms: D049109:Cell Proliferation; D005260:Female; D018380:Hematopoietic Stem Cell Transplantation; D006412:Hematopoietic Stem Cells; D006801:Humans; D053614:Janus Kinase 2 / Q000235:genetics*; D020125:Mutation, Missense; D009190:Myelodysplastic Syndromes / Q000628:therapy; D014184:Transplantation, Homologous
chemical_list: C507924:JAK2 protein, human; D053614:Janus Kinase 2